Printer Friendly

LEONID: Lung cancEr fusiOn geNes: a new dIagnostic Device.

EU contribution: EUR 1 704 000

Objective: The main scope of LEONID project is the development and validation of the clinical performance of a new diagnostic Nanostring-based device against existing standards (FISH and IHC) for the detection of in vitro biomarkers with predictive power of response to tyrosin kinase inhibitors used for lung cancer treatment. The device will be the first CE-IVD kit that detects all ALK, ROS1 and RET rearrangements with known and unknown partners in one multiplex assay and that, at the same time, identify the main variants of EML4-ALK.The clinical validation will be extended to the associated software for secondary analysis of data that will guarantee the results standardization, avoiding any personal interpretation. The new diagnostic device-software combination, that passed the technical feasibility analysis and is ready for experimental verification, will be the easiest, cheapest, fastest and standardized solution for ALK, ROS1 and RET fusions detection without losing sensitivity, specificity, robustness and reproducibility.The end users will be all molecular pathology laboratories supporting hospitals where lung cancer patients are treated, that (are going to) perform the analysis of fusion genes and want to reduce hands-on-time, error rate, and costs, saving specialized technical expertise and increasing the throughput of biomarkers and samples. At least 85 European medium-high throughput labs running 450 lung samples per year can be considered as potential customers.For Diatech Pharmacogenetics, the new device will be complementary to the existing products for pharmacogenetics analysis in oncology and will boost the company s approach of potential European distributors. GeneticLab can offer the test to low throughput labs and can speed up the entrance into the oncology business. BiMind can extend the panel of features of its proprietary oncology EHR dedicated to the analysis of laboratory tests results and can provide its new software through Diatech PGx or directly.

Participants:

BIMIND SAS DI MARINELLI MARCO VICO MAURIZIO EC

Italy

EU contribution: EUR 155 000

Italy

GENETICLAB S.R.L.

Italy

EU contribution: EUR 254 000

Italy

Project completion date : 2017-01-01 12:00:00

Major organization : DIATECH PHARMACOGENETICS SOCIETA A RESPONSABILITA LIMITATA

Address : Via Ignazio Silone, 1b,

60035 AN,

Country :Italy

Url : http://www.diatechpharmacogenetics.com/

Financier : European Union (EU),

Financier address : European Union (EU)

Rue de la Loi 200/Wetstraat 200,

B-1049 Bruxelles/Brussels,

Belgium

Tel: 32-2-2999696, 2993085

Fax: 32-2-2961749

Url: ec.europa.eu/

2015 Al Bawaba (Albawaba.com) Provided by SyndiGate Media Inc. ( Syndigate.info ).

COPYRIGHT 2015 SyndiGate Media Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2015 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Mena Report
Date:Jul 10, 2015
Words:400
Previous Article:StreetHopper: Disruptive Free Space Optics solution for small cell backhaul.
Next Article:MICROMIX-ECO-2015: Innovative active-uptake foliar nutrition technology capable of significantly reducing pesticide rates.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters